Sinogen Pharmaceutical has completed a Series B financing of tens of millions (CNY) to accelerate the global development of "oncolytic bacteria" drug

Recently, Guangzhou Sinogen Pharmaceutical has successfully completed a Series B financing of tens of millions CNY. This round of financing is led by PUXIN Capital, and co invested by Ningbo Zhuoxuan and Hebei Coastal Industry Investment. This round of funds will mainly be used for the global multi-center registered clinical research of SalMet-Vec® injection, the first tumor targeted amino acid metabolic pathway regulated oncolytic bacteria in the world, in the United States, Taiwan and Mainland China.

Dr. Allan Zijian Zhao, Chairman of Sinogen Pharmaceutical, said, "Sinogen Pharmaceutical has always focused on the research and development of global first-in-class innovative drugs. At a time when innovative drug financing is facing challenges, we are honored to receive investments from PUXIN Capital, Ningbo Zhuoxuan, and Hebei Coastal Industry Investment, which provide valuable and critical support for the multiple Phase II clinical trials we are currently conducting.".

About Sinogen Pharmaceutical

Sinogen Pharmaceuticals is a biopharmaceutical company jointly founded by four national high-level talents and experts, dedicated to the development of innovative biological anti-tumor drugs to meet the global demand for malignant tumor treatment market. Sinogen Pharmaceutical's independently developed oncolytic bacterial drug SalMet-Vec® is a first-in-class genetic engineering biological product that can accurately target and rapidly dissolve tumors. It carries specific methionine hydrolase through attenuated Salmonella carrier, depriving the necessary amino acids required for tumor growth, thus killing tumor and preventing tumor proliferation. It is an efficient and tumor-targeting product for broad-spectrum solid tumors.

Sinogen Pharmaceutical owns the complete intellectual property rights and global rights of SalMet-Vec® which has obtained 6 IND clinical trial approvals from the US FDA, Taiwan TFDA and Mainland China NMPA, and has obtained the FDA's Orphan Drug Designation(ODD) for the treatment of osteosarcoma, liver cancer and small cell lung cancer.

About PUXIN Capital

Shanghai PUXIN Capital Co., Ltd. was established on April 3, 2014, with a registered capital of CNY 200 million. It is a subsidiary of Shanghai Pudong Development Bank, Shanghai Trust, and Shanghai CITIC Asset Management, specializing in private fund management business. The company obtained a registration certificate as a private equity fund manager in 2014, becoming a professional institution engaged in private equity investment, venture capital and other private equity fund businesses. The company is one of the earliest private equity institutions in China to engage in private equity fund business, and its registered product asset size ranks among the top in the management scale of private equity fund management institutions in Shanghai. In 2023, it was awarded the top 100 Best State-owned Investment Institutions on the China Investment List.

About Hebei Coastal Industry Investment

Hebei Coastal Industrial Investment Fund Management Co., Ltd. is the first industrial investment fund management company in Hebei Province to be approved by the National Development and Reform Commission. It is led by Hebei Construction Investment Group Co., Ltd., the largest provincial state-owned investment company in Hebei Province, and jointly initiated by multiple private enterprises. The company was registered and established on August 30, 2013 in Caofeidian Industrial Zone, Tangshan City, with a registered capital of CNY 100 million.